Ensayos clínicos A continuación se enumeran ensayos clínicos actuales.7 estudios en Reumatología (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders Jacksonville, Fla. The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. A Study to Enroll Patients of Rheumatic Diseases and First-degree Relatives in a Biobank Rochester, Minn. The purpose of this study is to enroll rheumatic disease patients and first-degree relatives in a biobank, and to follow them over time to assess health outcomes and collect additional specimens. A Study to Evaluate Cardiopulmonary Complications in Systemic Sclerosis Rochester, Minn. The purpose of this study is to assess whether our not the percentage of pulmonary related vascular structures (PRVS) determined by the quantitative CT (Q-CT) tool CALIPER is a novel measure that can be used for the early detection of pulmonary vascular remodeling in patients with SSc. pulmonary related vascular structures The ANSWERS Study Rochester, Minn. The purpose of this study is to better understand Antiphospholipid syndrome (APS) pathophysiology and to aid development of targeted therapeutics. Phase 2 Safety And Efficacy Study Of Tulisokibart (MK-7240/PRA023) In Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD. Biomarkers in Autoimmune and Inflammatory Diseases Rochester, Minn. The purpose of this study is to identify biomarkers in people with autoimmune or inflammatory disease and in healthy people. We will use these biomarkers to develop tests that will help us better understand the same biomarkers in the blood of people who have autoimmune and inflammatory diseases. Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry Rochester, Minn. Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. A continuación se enumeran ensayos clínicos actuales.7 estudios en Reumatología (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders Jacksonville, Fla. The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. A Study to Enroll Patients of Rheumatic Diseases and First-degree Relatives in a Biobank Rochester, Minn. The purpose of this study is to enroll rheumatic disease patients and first-degree relatives in a biobank, and to follow them over time to assess health outcomes and collect additional specimens. A Study to Evaluate Cardiopulmonary Complications in Systemic Sclerosis Rochester, Minn. The purpose of this study is to assess whether our not the percentage of pulmonary related vascular structures (PRVS) determined by the quantitative CT (Q-CT) tool CALIPER is a novel measure that can be used for the early detection of pulmonary vascular remodeling in patients with SSc. pulmonary related vascular structures The ANSWERS Study Rochester, Minn. The purpose of this study is to better understand Antiphospholipid syndrome (APS) pathophysiology and to aid development of targeted therapeutics. Phase 2 Safety And Efficacy Study Of Tulisokibart (MK-7240/PRA023) In Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD. Biomarkers in Autoimmune and Inflammatory Diseases Rochester, Minn. The purpose of this study is to identify biomarkers in people with autoimmune or inflammatory disease and in healthy people. We will use these biomarkers to develop tests that will help us better understand the same biomarkers in the blood of people who have autoimmune and inflammatory diseases. Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry Rochester, Minn. Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. Solicite una consulta Conocimientos y categoríasInvestigación July 29, 2021 Comparte en: FacebookTwitter ReumatologíaSeccionesPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20476802 Centros y departamentos médicos Reumatología